Know Cancer

or
forgot password

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma


Phase 4
N/A
N/A
Not Enrolling
Both
Colorectal Cancer

Thank you

Trial Information

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma


Inclusion Criteria:



- Signed Informed Consent and Authorization document

- Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or
rectum

- Receiving Avastin as a component of first-line chemotherapy

- First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the
study

Exclusion Criteria:

- Patients who have contraindications for treatment with Avastin (see the Avastin
Package Insert) or who would incur excessive risks with Avastin treatment are
ineligible for this study.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Eric Hedrick, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Genentech

Authority:

United States: Institutional Review Board

Study ID:

AVF2941n

NCT ID:

NCT00097578

Start Date:

March 2004

Completion Date:

July 2008

Related Keywords:

  • Colorectal Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Colorectal Neoplasms

Name

Location

Genentech Central ContactSouth San Francisco, California  94080